Journal article
Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
- Abstract:
-
The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ). We evaluated the use of dihydroartemisinin-piperaquine (DHAPQ) as an alternative drug that could be used if SPAQ starts to lose efficacy. A total of 1,499 children 3 to 59 months old were randomized to receive SMC with SPAQ or DHAPQ over 3 months. The primary outcome measure...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Holley Cotec Pharmaceutical Company Ltd
More from this funder
Bibliographic Details
- Publisher:
- American Society for Microbiology Publisher's website
- Journal:
- Antimicrobial agents and chemotherapy Journal website
- Volume:
- 59
- Issue:
- 8
- Pages:
- 4387-4396
- Publication date:
- 2015-07-16
- Acceptance date:
- 2015-04-16
- DOI:
- EISSN:
-
1098-6596
- ISSN:
-
0066-4804
Item Description
- Language:
- English
- Pubs id:
-
pubs:522523
- UUID:
-
uuid:61e6bd72-3981-4fe0-bd64-7a90b24e83aa
- Local pid:
- pubs:522523
- Source identifiers:
-
522523
- Deposit date:
- 2016-04-01
Terms of use
- Copyright holder:
- American Society for Microbiology
- Copyright date:
- 2015
- Notes:
- Copyright © 2015, American Society for Microbiology. This is the accepted manuscript version of the article. The final version is available online from American Society for Microbiology at: http://dx.doi.org/10.1128/aac.04923-14
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record